Dianthus Therapeutics, Inc. $DNTH Stock Sold by Candriam S.C.A.

Candriam S.C.A. lessened its holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 11.2% during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 181,291 shares of the company’s stock after selling 22,923 shares during the period. Candriam S.C.A.’s holdings in Dianthus Therapeutics were worth $16,021,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the business. Walleye Capital LLC bought a new stake in Dianthus Therapeutics during the second quarter worth $1,743,000. SummitTX Capital L.P. boosted its position in Dianthus Therapeutics by 13.8% in the first quarter. SummitTX Capital L.P. now owns 100,044 shares of the company’s stock worth $8,396,000 after purchasing an additional 12,118 shares during the last quarter. California State Teachers Retirement System boosted its position in Dianthus Therapeutics by 155.5% in the first quarter. California State Teachers Retirement System now owns 40,584 shares of the company’s stock worth $3,406,000 after purchasing an additional 24,697 shares during the last quarter. Bank of America Corp DE purchased a new position in Dianthus Therapeutics in the second quarter worth $25,036,000. Finally, The Manufacturers Life Insurance Company bought a new position in Dianthus Therapeutics in the 2nd quarter valued at $6,125,000. 47.53% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

DNTH has been the subject of several research analyst reports. Citigroup initiated coverage on Dianthus Therapeutics in a research report on Friday, September 4th. They set a “buy” rating and a $156.00 target price for the company. HC Wainwright reiterated a “buy” rating and set a $158.00 target price on shares of Dianthus Therapeutics in a research note on Thursday, October 15th. Wedbush boosted their price target on shares of Dianthus Therapeutics from $105.00 to $122.00 and gave the stock an “outperform” rating in a report on Wednesday, August 5th. JPMorgan Chase & Co. began coverage on shares of Dianthus Therapeutics in a research report on Friday, September 11th. They set an “overweight” rating and a $135.00 price target for the company. Finally, Roth Capital started coverage on shares of Dianthus Therapeutics in a research report on Tuesday, October 27th. They set a “buy” rating and a $113.00 price target for the company. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Dianthus Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $128.77.

Dianthus Therapeutics Stock Up 4.6%

NASDAQ DNTH opened at $90.00 on Tuesday. The firm has a market cap of $4.93 billion, a P/E ratio of -22.56 and a beta of 1.47. The company’s 50 day moving average is $89.73 and its 200-day moving average is $85.78. Dianthus Therapeutics, Inc. has a 12-month low of $34.29 and a 12-month high of $117.88.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings data on Wednesday, November 4th. The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($0.94) by $0.13. The company had revenue of $1.21 million during the quarter, compared to the consensus estimate of $0.46 million. Dianthus Therapeutics had a negative net margin of 7,436.50% and a negative return on equity of 21.15%. Equities analysts expect that Dianthus Therapeutics, Inc. will post -3.60 EPS for the current year.

Insider Buying and Selling at Dianthus Therapeutics

In other Dianthus Therapeutics news, Director Simon Read sold 2,778 shares of the business’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $117.55, for a total transaction of $326,553.90. Following the sale, the director owned 2,778 shares of the company’s stock, valued at $326,553.90. The trade was a 50.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Simrat Randhawa sold 23,124 shares of the stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $106.41, for a total value of $2,460,624.84. Following the sale, the executive vice president owned 4,000 shares in the company, valued at approximately $425,640. This represents a 85.25% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 45,902 shares of company stock valued at $4,814,779 in the last 90 days. 3.02% of the stock is currently owned by company insiders.

About Dianthus Therapeutics

Dianthus Therapeutics is a clinical-stage biotechnology company developing medicines for autoimmune and inflammatory diseases involving the complement system, a part of the immune system. The company’s research focuses on selectively targeting complement activity that contributes to disease.